Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) Director Michael D. Kishbauch unloaded 495,812 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $9.40, for a total value of $4,660,632.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday. Separately, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $12.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $5.00. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.80.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 9.60% on Friday, hitting $9.25. The stock had a trading volume of 21,928,956 shares. Achillion Pharmaceuticals has a one year low of $2.26 and a one year high of $8.68. The stock has a 50-day moving average of $7.2 and a 200-day moving average of $4.54. The company’s market cap is $904.5 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.74 EPS for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.